IP Library › Granted Patent US 11,123,401
Granted Patent B2
US 11,123,401 · App. 16/228,181 · Granted Sep 21, 2021

Polypeptides binding to human complement C5

Inventors: Charlotta Berghard (Stockholm, SE); Magnus Berglund (Vendelsö, SE); Patrik Strömberg (Sollentuna, SE); Malin Lindborg (Saltsjö-Boo, SE); Elin Gunneriusson (Saltsjöbaden, SE); Joachim Feldwisch (Tyresö, SE)
Assignee: IPC Research, LLC
A61K38/164A61K38/16A61K47/64A61K47/68A61K47/6801C07K14/00C07K14/195C07K14/315C07K14/47A61K38/00C07K2319/00C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,123,401
App. No.
16/228,181
Granted
Sep 21, 2021
Kind
B2
Abstract

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX 2 X 3 X 4 A X 6 X 7 EID X 11 LPNL X 16 X 17 X 18 QW X 21 AFIX 25 X 26 LX 28 D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.

Claims (86)

1. A C5 binding polypeptide comprising:

(i) a C5 binding motif, BM, which motif: (a) forms part of a three-helix bundle protein domain and (b) comprises an amino acid sequence:

EX 2 X 3 X 4 A X 6 X 7 EID X 11 LPNL X 16 X 17 X 18 QW X 21 AFIX 25 X 26 LX 28 D (SEQ ID NO. 763);

wherein, independently of each other,

X 2 is selected from H, Q, S, T and V;

X 3 is selected from I, L, M and V;

X 4 is selected from A, D, E, H, K, L, N, Q, R, S, T and Y;

X 6 is selected from N and W;

X 7 is selected from A, D, E, H, N, Q, R, S and T;

X 11 is selected from A, E, G, H, K, L, Q, R, S, T and Y;

X 16 is selected from N and T;

X 17 is selected from I, L and V;

X 18 is selected from A, D, E, H, K, N, Q, R, S and T;

X 21 is selected from I, L and V;

X 25 is selected from D, E, G, H, N, S and T;

X 26 is selected from K and S; and

X 28 is selected from A, D, E, H, N, Q, S, T and Y, and

iii) additional C terminal and/or N terminal amino acids to facilitate production, purification, stabilization in vivo or in vitro, coupling, or detection of the polypeptide.

2. The C5 binding polypeptide according to claim 1 , wherein the additional amino acids are selected from a cysteine residue, a His 6 tag, a myc tag, a FLAG tag, and a half-life extending moiety.

3. The C5 binding polypeptide according to claim 2 , wherein the additional amino acids comprise a half-life extending moiety and wherein the half-life extending moiety is an Fc domain of an antibody.

4. The C5 binding polypeptide according to claim 2 , wherein the additional amino acids comprise a half-life extending moiety and the half-life extending moiety is an albumin binding domain.

5. The C5 binding polypeptide according to claim 4 , wherein the albumin binding domain is an albumin binding domain of streptococcal protein G.

6. The C5 binding polypeptide according to claim 4 , wherein the albumin-binding domain comprises the amino acid sequence of SEQ ID NO:759.

7. The C5 binding polypeptide according to claim 1 , wherein the amino acid sequence fulfills at least four of the following eight conditions I-VIII:

I. X2 is V;

II. X3 is selected from I and L;

III. X6 is W;

IV. X7 is selected from D and N;

V. X17 is selected from I and L;

VI. X21 is L;

VII. X25 is N;

VIII. X28 is D.

8. The C5 binding polypeptide according to claim 1 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-248.

9. The C5 binding polypeptide according to claim 1 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12, SEQ ID NO:20, SEQ ID NOs:23-24, SEQ ID NOs:26-28, SEQ ID NOs:32-35, SEQ ID NOs:38-39, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NOs:56-57, SEQ ID NO:59, SEQ ID NO:66, SEQ ID NOs:78-79, SEQ ID NO:87, SEQ ID NO:92, SEQ ID NO:106, SEQ ID NO:110, SEQ ID NO:119, SEQ ID NO:125, SEQ ID NO:141, SEQ ID NO:151, SEQ ID NO:161, SEQ ID NO:166, SEQ ID NO:187, SEQ ID NO:197, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:215 and SEQ ID NO:243.

10. The C5 binding polypeptide according to claim 1 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12.

11. The C5 binding polypeptide according to claim 1 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-5.

12. The C5 binding polypeptide according to claim 2 , wherein the amino acid sequence fulfills at least four of the following eight conditions I-VIII:

I. X2 is V;

II. X3 is selected from I and L;

III. X6 is W;

IV. X7 is selected from D and N;

V. X17 is selected from I and L;

VI. X21 is L;

VII. X25 is N;

VIII. X28 is D.

13. The C5 binding polypeptide according to claim 2 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-248.

14. The C5 binding polypeptide according to claim 2 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12, SEQ ID NO:20, SEQ ID NOs:23-24, SEQ ID NOs:26-28, SEQ ID NOs:32-35, SEQ ID NOs:38-39, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NOs:56-57, SEQ ID NO:59, SEQ ID NO:66, SEQ ID NOs:78-79, SEQ ID NO:87, SEQ ID NO:92, SEQ ID NO:106, SEQ ID NO:110, SEQ ID NO:119, SEQ ID NO:125, SEQ ID NO:141, SEQ ID NO:151, SEQ ID NO:161, SEQ ID NO:166, SEQ ID NO:187, SEQ ID NO:197, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:215 and SEQ ID NO:243.

15. The C5 binding polypeptide according to claim 2 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12.

16. The C5 binding polypeptide according to claim 2 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-5.

17. The C5 binding polypeptide according to claim 3 , wherein the amino acid sequence fulfills at least four of the following eight conditions I-VIII:

I. X2 is V;

II. X3 is selected from I and L;

III. X6 is W;

IV. X7 is selected from D and N;

V. X17 is selected from I and L;

VI. X21 is L;

VII. X25 is N;

VIII. X28 is D.

18. The C5 binding polypeptide according to claim 3 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-248.

19. The C5 binding polypeptide according to claim 3 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12, SEQ ID NO:20, SEQ ID NOs:23-24, SEQ ID NOs:26-28, SEQ ID NOs:32-35, SEQ ID NOs:38-39, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NOs:56-57, SEQ ID NO:59, SEQ ID NO:66, SEQ ID NOs:78-79, SEQ ID NO:87, SEQ ID NO:92, SEQ ID NO:106, SEQ ID NO:110, SEQ ID NO:119, SEQ ID NO:125, SEQ ID NO:141, SEQ ID NO:151, SEQ ID NO:161, SEQ ID NO:166, SEQ ID NO:187, SEQ ID NO:197, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:215 and SEQ ID NO:243.

20. The C5 binding polypeptide according to claim 3 , wherein the amino acid sequence is selected from any one of SEQ ID NOs: 1-12.

21. The C5 binding polypeptide according to claim 3 , wherein the amino acid sequence is selected from any one of SEQ ID NOs: 1-5.

22. The C5 binding polypeptide according to claim 4 , wherein the amino acid sequence fulfills at least four of the following eight conditions I-VIII:

I. X2 is V;

II. X3 is selected from I and L;

III. X6 is W;

IV. X7 is selected from D and N;

V. X17 is selected from I and L;

VI. X21 is L;

VII. X25 is N;

VIII. X28 is D.

23. The C5 binding polypeptide according to claim 4 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-248.

24. The C5 binding polypeptide according to claim 4 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12, SEQ ID NO:20, SEQ ID NOs:23-24, SEQ ID NOs:26-28, SEQ ID NOs:32-35, SEQ ID NOs:38-39, SEQ ID NO:41, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NOs:56-57, SEQ ID NO:59, SEQ ID NO:66, SEQ ID NOs:78-79, SEQ ID NO:87, SEQ ID NO:92, SEQ ID NO:106, SEQ ID NO:110, SEQ ID NO:119, SEQ ID NO:125, SEQ ID NO:141, SEQ ID NO:151, SEQ ID NO:161, SEQ ID NO:166, SEQ ID NO:187, SEQ ID NO:197, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:215 and SEQ ID NO:243.

25. The C5 binding polypeptide according to claim 4 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-12.

26. The C5 binding polypeptide according to claim 4 , wherein the amino acid sequence is selected from any one of SEQ ID NOs:1-5.

27. A polynucleotide encoding a C5 binding polypeptide according to claim 1 .

28. A polynucleotide encoding a C5 binding polypeptide according to claim 7 .

29. A polynucleotide encoding a C5 binding polypeptide according to claim 8 .

30. A polynucleotide encoding a C5 binding polypeptide according to claim 9 .

31. A polynucleotide encoding a C5 binding polypeptide according to claim 10 .

32. A polynucleotide encoding a C5 binding polypeptide according to claim 11 .

33. An expression vector comprising a polynucleotide encoding a C5 binding polypeptide according to claim 1 .

34. An expression vector comprising a polynucleotide encoding a C5 binding polypeptide according to claim 7 .

35. An expression vector comprising a polynucleotide encoding a C5 binding polypeptide according to claim 8 .

36. An expression vector comprising a polynucleotide encoding a C5 binding polypeptide according to claim 9 .

37. An expression vector comprising a polynucleotide encoding a C5 binding polypeptide according to claim 10 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2019
From: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
To: IPC RESEARCH, LLC
Reel/Frame 049392/0886 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2019
From: BERGHARD, CHARLOTTA; BERGLUND, MAGNUS; STRÖMBERG, PATRIK; LINDBORG, MALIN; GUNNERIUSSON, ELIN; FELDWISCH, JOACHIM
To: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Reel/Frame 048702/0590 →
Priority Claims (1)
SE 1250145-8 · Feb 20, 2012 · national
Continuity (3)
Continuation 15721507 · Sep 29, 2017
Continuation 14378522
Related Publication 20190167760A1 · Jun 6, 2019